ATE466933T1 - I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung - Google Patents

I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung

Info

Publication number
ATE466933T1
ATE466933T1 AT06744673T AT06744673T ATE466933T1 AT E466933 T1 ATE466933 T1 AT E466933T1 AT 06744673 T AT06744673 T AT 06744673T AT 06744673 T AT06744673 T AT 06744673T AT E466933 T1 ATE466933 T1 AT E466933T1
Authority
AT
Austria
Prior art keywords
variants
production
meganuclease variants
crei meganuclease
vectors
Prior art date
Application number
AT06744673T
Other languages
English (en)
Inventor
Frederic Paques
Philippe Duchateau
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36659837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE466933(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2005/000981 external-priority patent/WO2006097784A1/en
Priority claimed from PCT/IB2005/003083 external-priority patent/WO2007034262A1/en
Application filed by Cellectis filed Critical Cellectis
Application granted granted Critical
Publication of ATE466933T1 publication Critical patent/ATE466933T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06744673T 2005-03-15 2006-03-15 I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung ATE466933T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2005/000981 WO2006097784A1 (en) 2005-03-15 2005-03-15 I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
PCT/IB2005/003083 WO2007034262A1 (en) 2005-09-19 2005-09-19 Heterodimeric meganucleases and use thereof
PCT/IB2006/001203 WO2006097853A1 (en) 2005-03-15 2006-03-15 I-crei meganuclease variants with modified specificity, method of preparation and uses thereof

Publications (1)

Publication Number Publication Date
ATE466933T1 true ATE466933T1 (de) 2010-05-15

Family

ID=36659837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744673T ATE466933T1 (de) 2005-03-15 2006-03-15 I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung

Country Status (10)

Country Link
US (4) US20110158974A1 (de)
EP (5) EP2327773A1 (de)
JP (1) JP2008535484A (de)
AT (1) ATE466933T1 (de)
AU (1) AU2006224248B2 (de)
CA (1) CA2600033C (de)
DE (1) DE602006014107D1 (de)
DK (1) DK1863909T3 (de)
ES (1) ES2347684T3 (de)
WO (2) WO2006097854A1 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
ATE466933T1 (de) * 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2007060495A1 (en) † 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2008010009A1 (en) * 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
WO2008059317A1 (en) * 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
SG176487A1 (en) * 2006-11-14 2011-12-29 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
AU2007347328B2 (en) 2007-02-19 2013-03-07 Cellectis LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof
CN101616815A (zh) 2007-03-23 2009-12-30 阿文美驰技术有限责任公司 侧倾控制装置
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20140112904A9 (en) * 2007-06-06 2014-04-24 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
CA2691440A1 (en) 2007-06-29 2009-01-08 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
JP5763341B2 (ja) * 2007-09-27 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 生物学的活性のあるヌクレアーゼの迅速なインビボ同定法
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
WO2009074842A1 (en) * 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof
EP2247736B1 (de) 2008-02-29 2013-05-15 Monsanto Technology, LLC Maispflanze der linie mon87460 sowie zusammensetzungen und verfahren zu ihrer erkennung
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
JP2011519558A (ja) * 2008-04-28 2011-07-14 プレシジョン バイオサイエンシズ，インク． 合理的に設計されたｄｎａ結合タンパク質とエフェクタードメインとの融合分子
JP2011527906A (ja) 2008-07-14 2011-11-10 プレシジョン バイオサイエンシズ，インク． Ｉ−ＣｒｅＩ由来メガヌクレアーゼの認識配列およびその使用
EP2329017A2 (de) * 2008-08-04 2011-06-08 Cellectis Neues verfahren zur erzeugung von meganukleasen mit veränderten eigenschaften
US9273296B2 (en) 2008-09-08 2016-03-01 Cellectis Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (de) 2008-10-23 2010-04-28 Cellectis Meganuklease-Rekombinationssystem
AU2009333863B2 (en) 2008-12-17 2015-02-05 Corteva Agriscience Llc Targeted integration into the Zp15 locus
WO2010136981A2 (en) 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
EP2449135B1 (de) * 2009-06-30 2016-01-06 Sangamo BioSciences, Inc. Schnelles screening biologisch aktiver nukleasen und isolation nukleasemodifizierter zellen
WO2011007193A1 (en) 2009-07-17 2011-01-20 Cellectis Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
WO2011021062A1 (en) 2009-08-21 2011-02-24 Cellectis Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof
WO2011036640A2 (en) 2009-09-24 2011-03-31 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
CA2793596A1 (en) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
WO2011101696A1 (en) 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
EP2539445B1 (de) 2010-02-26 2018-03-21 Cellectis Verwendung von endonukleasen für den einsatz von transgenen in safe-harbor-loci
US20130198897A1 (en) * 2010-03-22 2013-08-01 Philip Morris Products S.A. Modifying enzyme activity in plants
EP2569424A1 (de) 2010-05-12 2013-03-20 Cellectis Eine dna-zielsequenz vom dystrophingen abspaltende meganukleasevarianten und ihre verwendung
EP2569435A1 (de) 2010-05-12 2013-03-20 Cellectis Eine dna-zielsequenz von einem rhodopsin-gen abspaltende meganukleasevarianten und ihre verwendung
CA2802822A1 (en) 2010-06-15 2012-01-05 Cellectis Method for improving cleavage of dna by endonuclease sensitive to methylation
EP2591098A2 (de) 2010-07-07 2013-05-15 Cellectis Eine dna-zielsequenz im nanog-gen abspaltende meganukleasevarianten und ihre verwendung
WO2012010976A2 (en) 2010-07-15 2012-01-26 Cellectis Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof
WO2012007848A2 (en) 2010-07-16 2012-01-19 Cellectis Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof
CA2807270A1 (en) 2010-08-02 2012-02-09 Cellectis Method for targeted genomic events in diatoms
SG189482A1 (en) 2010-10-27 2013-05-31 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
AR085533A1 (es) 2011-03-23 2013-10-09 Pioneer Hi Bred Int Metodos de produccion de un locus de rasgos transgenicos complejo
WO2012138901A1 (en) 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
CA2834375C (en) 2011-04-27 2020-07-14 Amyris, Inc. Methods for genomic modification
CA2834679C (en) 2011-05-02 2021-12-28 Board Of Regents Of The University Of Nebraska Method for producing a plant with useful traits by suppressing msh1 gene
WO2012158778A1 (en) 2011-05-16 2012-11-22 Cellectis S.A. Doubly secure transgenic algae or cyanobacteria strains to prevent their establishment and spread in natural ecosystems
CA2844470A1 (en) 2011-06-21 2013-05-10 Pioneer Hi-Bred International, Inc. Methods and compositions for producing male sterile plants
EP2729567B1 (de) 2011-07-08 2016-10-05 Cellectis Verfahren zur erhöhung der wirkung einer doppelsträngigen bruchinduzierten mutagenese
BR112014002622A2 (pt) 2011-08-03 2019-09-24 Du Pont método para introduzir no genoma de uma célula vegetal um sítio alvo para a integração específica de sítio, célula vegetal, parte de planta, planta ou semente, método para integrar um polinucleotídeo de interesse em um sítio alvo no genoma de uma célula vegetal
AU2013233946A1 (en) 2012-03-13 2014-10-09 University Of Guelph Methods of increasing tolerance to heat stress and amino acid content of plants
WO2013136274A1 (en) 2012-03-13 2013-09-19 University Of Guelph Myb55 promoter and use thereof
US20150184173A1 (en) 2012-05-04 2015-07-02 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
EP2877488B1 (de) 2012-07-24 2021-02-24 Cellectis Neue modulare basenspezifische nukleinsäurebindende domänen aus burkholderia-rhizoxinica-proteinen
US20160272980A1 (en) 2012-11-16 2016-09-22 Total Marketing Services Method for targeted modification of algae genomes
CA2895117A1 (en) 2012-12-13 2014-06-19 James W. Bing Precision gene targeting to a particular locus in maize
WO2014102688A1 (en) 2012-12-27 2014-07-03 Cellectis New design matrix for improvement of homology-directed gene targeting
EP2951295B1 (de) 2013-02-01 2018-08-01 Cellectis Chimäre tevi-endonukleasen und deren bevorzugte spaltungsorte
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
CN105189788B (zh) 2013-03-12 2018-07-13 纳幕尔杜邦公司 用于鉴定罕见切割工程化双链断裂诱导剂的变体识别位点的方法及其组合物和用途
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
CA2912375C (en) 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
US10767188B2 (en) 2013-09-25 2020-09-08 Nutech Ventures Methods and compositions for obtaining useful plant traits
KR102251168B1 (ko) 2013-10-25 2021-05-13 셀렉티스 고 반복 모티프를 포함하는 dna 서열에 대한 효율적이고 특이적인 표적화를 위한 희소-절단 엔도뉴클레아제의 설계
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
EP3460063B1 (de) 2013-12-11 2024-03-13 Regeneron Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur gezielten modifikation eines genoms
US9476065B2 (en) 2013-12-19 2016-10-25 Amyris, Inc. Methods for genomic integration
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
RU2752933C2 (ru) 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
JP2017513472A (ja) 2014-04-11 2017-06-01 セレクティスＣｅｌｌｅｃｔｉｓ アルギニンおよび／またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
DK3161128T3 (en) 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
EP3845655B1 (de) 2014-10-01 2025-01-01 The General Hospital Corporation Verfahren zur erhöhung der effizienz von nucleaseinduzierter homologiegerichteter reparatur
BR112017007770A2 (pt) 2014-10-15 2018-01-16 Regeneron Pharma cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
KR102270479B1 (ko) * 2014-10-15 2021-06-29 삼성전자주식회사 디스플레이 장치, 서버, 및 디스플레이 장치의 제어방법
WO2016100333A1 (en) 2014-12-15 2016-06-23 Syngenta Participations Ag Pesticidal microrna carriers and use thereof
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
EP3283501B1 (de) 2015-04-16 2023-01-04 William Marsh Rice University Stöchiometrische abstimmung von nukleinsäurehybridisierungssonden durch hilfsoligonukleotidspezies
CA2994746A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2017079428A1 (en) 2015-11-04 2017-05-11 President And Fellows Of Harvard College Site specific germline modification
JP7012645B2 (ja) 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
WO2017123559A2 (en) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US11293033B2 (en) 2016-05-18 2022-04-05 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
CN109803530A (zh) 2016-07-29 2019-05-24 瑞泽恩制药公司 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
WO2018076335A1 (en) 2016-10-31 2018-05-03 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Compositions and methods for enhancing abiotic stress tolerance
CA3050715A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
GB201709308D0 (en) * 2017-06-12 2017-07-26 Univ Manchester Variant nucleotide library
HUE073358T2 (hu) 2017-08-29 2026-01-28 Kws Saat Se & Co Kgaa Továbbfejlesztett kék aleuron és egyéb szegregációs rendszerek
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
AU2019216269B2 (en) 2018-01-30 2025-05-01 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
WO2019177976A1 (en) 2018-03-12 2019-09-19 Pioneer Hi-Bred International, Inc. Methods for plant transformation
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
WO2020131632A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
JP7506686B2 (ja) 2019-04-04 2024-06-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化凝固因子１２遺伝子座を含む非ヒト動物
AU2020253531C1 (en) 2019-04-04 2022-06-16 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
GB201909228D0 (en) 2019-06-27 2019-08-14 Azeria Therapeutics Ltd Screen for inhibitors
AU2020322021A1 (en) 2019-07-30 2022-02-10 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
JP2024506316A (ja) 2021-02-09 2024-02-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リベリバクター属種によって引き起こされる植物の病気に対する防御に関与する免疫調節因子
EP4337769A1 (de) 2021-05-10 2024-03-20 SQZ Biotechnologies Company Verfahren zur abgabe von genomeditierungsmolekülen an den zellkern oder cytosol einer zelle und verwendungen davon
KR20240028362A (ko) 2021-05-28 2024-03-05 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
CN118119702A (zh) 2021-10-14 2024-05-31 隆萨销售股份有限公司 用于细胞外囊泡产生的经修饰的生产者细胞
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
KR20240128067A (ko) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 랜딩 패드 세포주의 생성
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
JP2025519070A (ja) 2022-05-17 2025-06-24 エンヴェロップ セラピューティクス， インコーポレイテッド 効率的ｉｎ ｖｉｖｏ送達のための組成物および方法
US20260083846A1 (en) 2022-05-19 2026-03-26 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
AU2023329392A1 (en) 2022-08-25 2025-02-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
EP4777526A1 (de) 2023-09-12 2026-07-22 Aadigen, LLC Verfahren und zusammensetzungen zur behandlung oder prävention von krebs

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US20100151556A1 (en) 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US8206965B2 (en) * 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US9447434B2 (en) * 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
AU2003290518A1 (en) * 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
EP1591521A1 (de) 2004-04-30 2005-11-02 Cellectis I-Dmo I -Derivate mit erhöhter Aktivität bei 37 Grad C und deren Verwendung
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
DK3246403T3 (da) * 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
SG176487A1 (en) 2006-11-14 2011-12-29 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
WO2008093152A1 (en) 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
AU2007347328B2 (en) 2007-02-19 2013-03-07 Cellectis LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof
WO2008149176A1 (en) 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
US20140112904A9 (en) 2007-06-06 2014-04-24 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
WO2009074842A1 (en) 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof
US9273296B2 (en) 2008-09-08 2016-03-01 Cellectis Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (de) 2008-10-23 2010-04-28 Cellectis Meganuklease-Rekombinationssystem
WO2010122367A2 (en) 2009-04-21 2010-10-28 Cellectis Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
WO2010136981A2 (en) 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof

Also Published As

Publication number Publication date
US7897372B2 (en) 2011-03-01
US20100021448A1 (en) 2010-01-28
EP1863909B1 (de) 2010-05-05
EP2327771A1 (de) 2011-06-01
ES2347684T3 (es) 2010-11-03
US8715992B2 (en) 2014-05-06
CA2600033A1 (en) 2006-09-21
EP2327772A1 (de) 2011-06-01
WO2006097854A1 (en) 2006-09-21
WO2006097853A1 (en) 2006-09-21
US20110072527A1 (en) 2011-03-24
US20120258537A1 (en) 2012-10-11
AU2006224248B2 (en) 2011-01-06
CA2600033C (en) 2015-06-02
EP2325307A1 (de) 2011-05-25
EP1863909A1 (de) 2007-12-12
AU2006224248A1 (en) 2006-09-21
DK1863909T3 (da) 2010-08-30
US20110158974A1 (en) 2011-06-30
JP2008535484A (ja) 2008-09-04
EP1863909B2 (de) 2014-09-10
EP2327773A1 (de) 2011-06-01
DE602006014107D1 (de) 2010-06-17

Similar Documents

Publication Publication Date Title
DE602006014107D1 (de) I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
KR102623312B1 (ko) Ruvc 도메인이 존재하는 효소
ES2760508T3 (es) Métodos y composiciones para la modificación genética dirigida a través de la transformación múltiple en una sola etapa
JP6688231B2 (ja) 標的遺伝子座を修飾するための方法及び組成物
WO2019103442A3 (ko) CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도
Fujihara et al. CRISPR/Cas9-based genome editing in mice by single plasmid injection
WO2007049156A3 (en) I-CreI HOMING ENDONUCLEASE VARIANTS HAVING NOVEL CLEAVAGE SPECIFICITY AND USE THEREOF
ATE501265T1 (de) Verfahren zur herstellung von l-lysin unter verwendung von escherichia coli
ATE500337T1 (de) Verfahren zur durchführung homologer rekombinationen in pflanzen
DE69833457D1 (de) Neuartige methode zur integration von fremd-dna ins eukaryotische genom
DE502007003734D1 (de) Verfahren zur enzymatischen herstellung von 2-hydroxy-2-methylcarbonsäuren
JP2013531489A5 (de)
Laborda-Mansilla et al. Advancements in Golden Gate cloning: A comprehensive review
Kumar Genome editing to epigenome editing: Towards unravelling the enigmas in developmental biology
CA3036443A1 (en) Compositions and methods for polynucleotide assembly
AR130459A1 (es) Sistema y método de edición genómica basados en adn polimerasa
ATE493500T1 (de) Pflanzen mit veränderten wachstumseigenschaften und verfahren zu deren herstellung
BRPI0407296A (pt) ácidos nucléicos que codificam agentes antelmìnticos e plantas produzidas a partir deles
AR041953A1 (es) Secuencias de adn a partir de la region genomica tcd de photorhabdus luminiscens
ATE508189T1 (de) Zur beschleunigung der genexpressionbei einer mässig niedrigen temperatur fähige sequenz
ATE375386T1 (de) Verfahren zur herstellung von arachidonsäure in transgenen organismen
DE60233169D1 (de) Verfahren zur herstellung umwelt sicherer transgener organismen
NZ592147A (en) Delta-8 desaturase genes, enzymes encoded thereby and uses thereof
WO2004005474A3 (en) A robust, inducible cardiac preferred expression system for transgenesis
Bhatia et al. Biotechnology and Genetic Engineering in the Twenty-First Century

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1863909

Country of ref document: EP